


| | | | |
|---|--|---|--|
| RECORDATION FORM COVER SHEET | | U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office | |
| PATENTS ONLY | | Attorney Docket Number A3592Q-US-NP | |
| To the Honorable Commissioner of Patents and Trademarks: Please record the attached original assignment document. | | | |
| 1. Name of all Party(ies) conveying an interest: 1. Adela Goredema 2. Rina Carlini 3. Marcel P. Breton 4. Jeffrey H. Banning | | 2. Name and Address of receiving Party(ies): Xerox Corporation 800 Long Ridge Road P.O. Box 1600 Stamford, CT 06904-1600 | |
| Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No | | Additional name(s) and address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No | |
| 3. Nature of Conveyance: <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other _____ | | Assignment Execution Date(s): 2/2/2005 Title: PHASE CHANGE INKS CONTAINING TRANS-1,2-CYCLOHEXANE BIS[UREA-URETHANE] COMPOUNDS | |
| 4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date of the application is: 2/2/2005 A. Patent Application No.(s) 11/004,332 B. Patent No.(s) _____ Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No | | | |
| 5. Name and Address of party to whom correspondence concerning document should be mailed: Patent Documentation Center Xerox Corporation 100 Clinton Avenue South Xerox Square 20th Floor Rochester, NY 14644 CUSTOMER NUMBER: 25453 | | 6. Total number of applications and patents involved = 1 7. Total Fee (37 CFR 3.41): \$ 40.00 <input type="checkbox"/> Enclosed <input checked="" type="checkbox"/> Authorized to be charged to Deposit Account 8. Deposit Account Number: 24-0025 | |
| DO NOT USE THIS SPACE | | | |
| 9. Statement and signature. <i>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.</i> Name of Person Signing Judith L. Byorick Date February 14, 2005 Signature  Total number of pages comprising cover sheet 1 | | | |
| Rev 08/2003 | | | |

CH \$40.00 240025 11004332

ASSIGNMENT

Attorney Docket No.: A3592Q-US-NP

The undersigned is/are the named inventor(s) (the "Inventor(s)") on a United States patent application entitled **PHASE CHANGE INKS CONTAINING TRANS-1,2-CYCLOHEXANE BIS[UREA-URETHANE] COMPOUNDS**

(the "Application") for inventions disclosed or claimed therein (the "Invention(s)"),

which Application:

- ☐ is being executed concurrently herewith,
☐ was first executed on
☒ was filed on **12/4/04** as Application Number **11/004,332**.
☐ claims the benefit of U.S. Provisional Application(s) No(s). filed .

Xerox Corporation, a New York Corporation, on behalf of itself, its successors and assigns, and its legal representatives ("Xerox"), is entitled to all rights in the Application and the Invention(s), and the full cooperation of the Inventor(s).

For valuable consideration, the receipt of which is hereby acknowledged, the Inventor(s) hereby sell(s), assign(s), and transfer(s) to Xerox the entire and exclusive right, title and interest in the Application and the Invention(s), in and for the United States, its territories, and all foreign countries, including all applications, patents, design registrations and publications obtained or derived therefrom, world wide, and all priority rights under all present or future conventions and treaties, and any provisional applications for which priority is claimed in the Application; and

- (1) request the U.S. Commissioner of Patents to issue all U.S. Letters Patent granted thereon to Xerox;
- (2) agree that Xerox may apply for and receive all foreign Letters Patent thereon;
- (3) agree to execute all papers and take all actions necessary or desirable in connection therewith requested by Xerox; and
- (4) authorize Xerox to subsequently enter the Application Number on this Assignment, if not already entered above.

Adela Goredema

Date _____

Rina Carlini

Date _____

Marcel P. Breton

Date _____

Jeffrey H. Banning

Date Feb 2, 2005

ASSIGNMENT

Attorney Docket No.: A3592Q-US-NP

The undersigned is/are the named inventor(s) (the "Inventor(s)") on a United States patent application entitled **PHASE CHANGE INKS CONTAINING TRANS-1,2-CYCLOHEXANE BIS[UREA-URETHANE] COMPOUNDS**

(the "Application") for inventions disclosed or claimed therein (the "Invention(s)"), which Application:

- ☐ is being executed concurrently herewith,
☐ was first executed on
☒ was filed on **12/4/04** as Application Number **11/004,332**.
☐ claims the benefit of U.S. Provisional Application(s) No(s). filed .


Xerox Corporation, a New York Corporation, on behalf of itself, its successors and assigns, and its legal representatives ("Xerox"), is entitled to all rights in the Application and the Invention(s), and the full cooperation of the Inventor(s).

For valuable consideration, the receipt of which is hereby acknowledged, the Inventor(s) hereby sell(s), assign(s), and transfer(s) to Xerox the entire and exclusive right, title and interest in the Application and the Invention(s), in and for the United States, its territories, and all foreign countries, including all applications, patents, design registrations and publications obtained or derived therefrom, world wide, and all priority rights under all present or future conventions and treaties, and any provisional applications for which priority is claimed in the Application; and


- (1) request the U.S. Commissioner of Patents to issue all U.S. Letters Patent granted thereon to Xerox;
- (2) agree that Xerox may apply for and receive all foreign Letters Patent thereon;
- (3) agree to execute all papers and take all actions necessary or desirable in connection therewith requested by Xerox; and
- (4) authorize Xerox to subsequently enter the Application Number on this Assignment, if not already entered above.



Adela Goredema

Date Feb 2, 2005

Rina Carlini

Date Feb 2, 2005

Marcel P. Breton

Date Feb 2, 2005

Jeffrey H. Banning

Date _____